The early termination of an NIH grant at the University of Alabama halted a near-complete study on COVID-19 in immunocompromised children, leaving years of research and investment without results that could have improved the care of vulnerable children.
An NIH-funded research project at the University of Alabama at Birmingham studying immune response to COVID-19 in immunocompromised children, including those undergoing cancer treatment, was terminated one year early in 2025, despite being in its final phase after four years of work and investment. The study was uniquely positioned to answer critical unresolved questions, including on how long these vulnerable children shed the virus, how their immune systems respond to infection and vaccination, and how clinical outcomes compare to those of healthy children, and why immunocompromised children appear to fare better than adults with similar conditions. The grant was terminated before analyses could be completed, leaving a significant collection of biological samples unanalyzed and forgoing an opportunity to generate important evidence to inform vaccination strategies, infection control, and care for high-risk pediatric patients.
Beyond the scientific setback, the termination had significant human and institutional consequences. The research team lost approximately $800,000 in expected federal funding and was forced to lay off two staff members and reduce another to part-time status, leaving the lab operating with only skeletal capacity. For junior researchers on the team, the loss represented a major career disruption, halting progress on publications and momentum needed for career advancement. Most concerning, the early termination means that years of federally funded research and data collection will never be fully analyzed or translated into results, squandering both taxpayer investment and missing a critical opportunity to generate actional knowledge to protect children's health.